Apellis stock toppled Tuesday after third-quarter sales of the company's eye drug, Syfovre, widely missed Wall Street's expectations. Please watch the video at Investors.com - How To Buy Stocks ...

His PCB hooks right up to the GPIO pins of the internal Raspberry Pi Zero, making interfacing with the dome switch keyboard very easy. The board also holds the power management hardware for the ...

While Syfovre’s revenue miss is no doubt disappointing, the drug remained the market leader in GA with more than 88,500 doses delivered to physicians in the third quarter, Apellis said in its ...

Last week we saw the announcement of the new Raspberry Pi Zero 2 W, which is basically an improved quad-core version of the Pi Zero — more comparable in speed to the Pi 3B+, but in the smaller ...

While the company’s topline expanded ~78% to $196.8M, it still missed Wall Street forecasts by $2.99M as Syfovre net product revenue from the U.S. fell unexpectedly. The newly launched drug for ...

“The third quarter was marked by continued progress, including growth in SYFOVRE vial demand and the positive Phase 3 VALIANT study results in C3G and IC-MPGN. While SYFOVRE net sales fell short ...

Empaveli could achieve peak sales of $700 million by 2031, targeting C3G and IC-MPGN markets. Syfovre is expected to reach U.S. peak sales of $2 billion by 2030, driven by strong demand and ...

The company’s drug, Syfovre, experienced a slight decline in sales for Q3, primarily due to increased gross-to-net adjustments that affected revenue, despite a 7% increase in commercial vial ...

Apellis Pharmaceuticals is marketing Syfovre, a new treatment for patients with a leading cause of blindness. Syfovre is approved in the U.S., but Apellis' stock tanked after European regulators ...

Apellis Pharma has said it will seek a re-evaluation of its marketing application for Syfovre for eye disease geographic atrophy (GA) after the EMA’s human medicines committee turned it down for ...

Much of the growth came from Syfovre, the first Food and Drug Administration (FDA)-approved treatment for eye disorder geographic atrophy (GA). Sales of the drug more than doubled in the third ...